Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies

References

• Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62. doi:10.12703/r/10-62
   PubMedGoogle Scholar
• Murakami M. Guselkumab for the treatment of palmoplantar pustulosis. Expert Opin Biol Ther. 2020;20(8):841–852. doi:10.1080/14712598.2020.1760244
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799. doi:10.1111/jdv.14386
   PubMed Web of Science ®Google Scholar
• Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: recent Advances in Etiopathogenesis and Emerging Treatments. Am J Clin Dermatol. 2020;21(3):355–370. doi:10.1007/s40257-020-00503-5
   PubMed Web of Science ®Google Scholar
• Xu JM, Wang HM, Jin HZ. An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations. Expert Rev Clin Immunol. 2023;19(5):499–516. doi:10.1080/1744666X.2023.2185775
   PubMed Web of Science ®Google Scholar
• Andersen YMF, Augustin M, Petersen J, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol. 2019;181(5):976–982. doi:10.1111/bjd.17832
   PubMed Web of Science ®Google Scholar
• Misiak-Galazka M, Wolska H, Galazka A, Kwiek B, Rudnicka L. General Characteristics and Comorbidities in Patients with Palmoplantar Pustulosis. Acta Dermatovenerol Croat. 2018;26(2):109–118.
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J Dermatol. 2013;40(11):857–863. doi:10.1111/1346-8138.12272
   PubMed Web of Science ®Google Scholar
• Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A. Involvement of Molecular Mechanisms between T/B Cells and IL-23: from Palmoplantar Pustulosis to Autoimmune Diseases. Int J Mol Sci. 2022;23(15):8261. doi:10.3390/ijms23158261
   PubMed Web of Science ®Google Scholar
• Xiaoling Y, Chao W, Wenming W, Feng L, Hongzhong J. Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. Clin Exp Dermatol. 2019;44(1):52–57. doi:10.1111/ced.13689
   PubMed Web of Science ®Google Scholar
• Paik K, Kim BR, Youn SW. Evaluation of the area subscore of the Palmoplantar Pustulosis Area and Severity Index using an attention U-net deep learning algorithm. J Dermatol. 2023;50(6):787–792. doi:10.1111/1346-8138.16752
   PubMed Web of Science ®Google Scholar
• Nagendran A, Hanumanthu V, Dogra S, Narang T, Venkata Maha Pinnaka L. Validation and usability of modified palmoplantar psoriasis area and severity index in patients with palmoplantar psoriasis: a prospective longitudinal cohort study. Indian J Dermatol Venereol Leprol. 2023;1–8. doi:10.25259/IJDVL_712_2022
   PubMedGoogle Scholar
• Carr D, Tusa MG, Carroll CL, et al. Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatol Treatment. 2008;19(2):97–100. doi:10.1080/09546630701364776
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Munshi M, Bossart S, et al. Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis. Bioengineering. 2022;9(8). doi:10.3390/bioengineering9080387
   PubMedGoogle Scholar
• Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85(3):572–581. doi:10.1016/j.jaad.2021.02.057
   PubMed Web of Science ®Google Scholar
• Ataş H, Gönül M. Insulin resistance, diabetes mellitus and thyroid dysfunction in patients with palmoplantar pustulosis: a case-controlled study. Postepy Dermat Alergologii. 2017;34(3):268–272. doi:10.5114/pdia.2016.61630
   PubMed Web of Science ®Google Scholar
• Serizawa N, Okazaki S, Otsuka Y, et al. Dietary habits in Japanese patients with palmoplantar pustulosis. J Dermatol. 2021;48(3):366–375. doi:10.1111/1346-8138.15719
   PubMed Web of Science ®Google Scholar
• Kim DH, Lee JY, Cho SI, Jo SJ. Risks of Comorbidities in Patients With Palmoplantar Pustulosis vs Patients With Psoriasis Vulgaris or Pompholyx in Korea. JAMA Dermatol. 2022;158(6):650–660. doi:10.1001/jamadermatol.2022.1081
   PubMed Web of Science ®Google Scholar
• Mazloom SE, Yan D, Hu JZ, et al. TNF-α inhibitor-induced psoriasis: a decade of experience at the Cleveland Clinic. J Am Acad Dermatol. 2020;83(6):1590–1598. doi:10.1016/j.jaad.2018.12.018
   PubMed Web of Science ®Google Scholar
• López-Robles A, Queiro R, Alperi M, Alonso S, Riestra JL, Ballina J. Psoriasis and psoriasiform lesions induced by TNFα antagonists: the experience of a tertiary care hospital from northern Spain. Rheumatol Int. 2012;32(12):3779–3783. doi:10.1007/s00296-011-2265-4
   PubMed Web of Science ®Google Scholar
• Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196–205. doi:10.1111/apt.14822
   PubMed Web of Science ®Google Scholar
• Thein D, Egeberg A, Skov L, Loft N. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: a Danish Nationwide Cohort Study. JAMA Dermatol. 2022;158(9):997–1004. doi:10.1001/jamadermatol.2022.2360
   PubMed Web of Science ®Google Scholar
• Kim M, Yang S, Kim BR, Youn SW. Nail involvement features in palmoplantar pustulosis. J Dermatol. 2021;48(3):360–365. doi:10.1111/1346-8138.15716
   PubMed Web of Science ®Google Scholar
• Kim YC, Lee ES, Chung PS, Rhee CK. Recalcitrant palmoplantar pustular psoriasis successfully treated with topical 5-aminolaevulinic acid photodynamic therapy [14]. Clin Exp Dermatol. 2005;30(6):723–724. doi:10.1111/j.1365-2230.2005.01905.x
   PubMed Web of Science ®Google Scholar
• Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol. 1992;72(1):69–71. doi:10.2340/00015555726971
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: a randomized, double-blind, placebo-controlled trial. J Dermatol. 2016;43(3):288–293. doi:10.1111/1346-8138.13064
   PubMed Web of Science ®Google Scholar
• Muro M, Kawakami H, Matsumoto Y, Abe N, Tsuboi R, Okubo Y. Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomized, left-right comparison study. J Dermatolog Treat. 2016;27(1):51–53. doi:10.3109/09546634.2015.1052036
   PubMed Web of Science ®Google Scholar
• Goette DK, Morgan AM, Fox BJ, Horn RT. Treatment of palmoplantar pustulosis with intralesional triamcinolone injections. Arch Dermatol. 1984;120(3):319–323. doi:10.1001/archderm.1984.01650390041008
   PubMedGoogle Scholar
• Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol. 1991;71(6):540–542. doi:10.2340/0001555571540542
   PubMed Web of Science ®Google Scholar
• Horiuchi Y. Palmoplantar pustulosis treated with oral rinse using ozone nanobubble water: a case series. Dermatol Ther. 2020;33(6). doi:10.1111/dth.13924
   PubMed Web of Science ®Google Scholar
• Mizawa M, Makino T, Inami C, Shimizu T. Jumihaidokuto (Shi-Wei-Ba-Du-Tang), a kampo formula, decreases the disease activity of palmoplantar pustulosis. Dermatol Res Pract. 2016;2016:1–4. doi:10.1155/2016/4060673
   Google Scholar
• Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol. 1991;124(6):581–584. doi:10.1111/j.1365-2133.1991.tb04955.x
   PubMed Web of Science ®Google Scholar
• Murray D, Warin AP. Photochemotherapy for persistent palmoplantar pustulosis (PPP) [proceedings]. Br J Dermatol. 1979;101(Suppl 17):13–14.
   PubMedGoogle Scholar
• Jansén CT, Malmiharju T. Inefficacy of topical methoxalen plus UVA for palmoplantar pustulosis. Acta Derm Venereol. 1981;61(4):354–356. doi:10.2340/0001555561354356
   PubMed Web of Science ®Google Scholar
• Paul R, Jansén CT. Suppression of palmoplantar pustulosis symptoms with oral 8-methoxypsoralen and high-intensity UVA irradiation. Dermatologica. 1983;167(5):283–285. doi:10.1159/000249798
   PubMedGoogle Scholar
• Riad K, Felix P, Dorit S, Gregory K, Nadim K, Henri T. The use of topical PUVA for palmoplantar dermatoses. J Dermatolog Treat. 2006;17(5):304–307. doi:10.1080/09546630600866442
   PubMed Web of Science ®Google Scholar
• Agren-Jonsson S, Tegner E. PUVA therapy for palmoplantar pustulosis. Acta Derm Venereol. 1985;65(6):531–535. doi:10.2340/0001555565531535
   PubMed Web of Science ®Google Scholar
• Su LN, Xu X, Tang L, Yu N, Ding YF. UVA1 phototherapy in the treatment of palmoplantar pustulosis: a pilot prospective study. Lasers Med Sci. 2016;31(8):1641–1643. doi:10.1007/s10103-016-2031-7
   PubMed Web of Science ®Google Scholar
• Su LN, Ren J, Cheng SM, Liu JL, Ding YF, Zhu NW. UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study. Lasers Med Sci. 2017;32(8):1819–1823. doi:10.1007/s10103-017-2280-0
   PubMed Web of Science ®Google Scholar
• Engin B, Oguz O. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses. Int J Dermatol. 2005;44(4):337–339. doi:10.1111/j.1365-4632.2004.02153.x
   PubMed Web of Science ®Google Scholar
• Kawada A, Matsuda H, Oiso N. Efficacy and safety of targeted narrowband ultraviolet B therapy using a flat-type fluorescent lamp for the treatment of palmoplantar pustulosis. J Dermatol. 2013;40(9):754–755. doi:10.1111/1346-8138.12228
   PubMed Web of Science ®Google Scholar
• Fumimori T, Tsuruta D, Kawakami T, Ohata C, Furumura M, Hashimoto T. Effect of monochromatic excimer light on palmoplantar pustulosis: a clinical study performed in a private clinic by a dermatological specialist. J Dermatol. 2013;40(12):1004–1007. doi:10.1111/1346-8138.12302
   PubMed Web of Science ®Google Scholar
• Furuhashi T, Torii K, Kato H, Nishida E, Saito C, Morita A. Efficacy of excimer light therapy (308 nm) for palmoplantar pustulosis with the induction of circulating regulatory T cells. Exp Dermatol. 2011;20(9):768–770. doi:10.1111/j.1600-0625.2011.01316.x
   PubMed Web of Science ®Google Scholar
• Peng C, Hu Y, Chen W, et al. A randomized prospective study of different dose regimens using the 308-nm excimer laser in the treatment of palmoplantar pustulosis. Dermatol Ther. 2021;34(5):e15079. doi:10.1111/dth.15079
   PubMed Web of Science ®Google Scholar
• Fenton L, Dawe RS. Six years’ experience of grenz ray therapy for the treatment of inflammatory skin conditions. Clin Exp Dermatol. 2016;41(8):864–870. doi:10.1111/ced.12960
   PubMed Web of Science ®Google Scholar
• Fairris GM, Jones DH, Mack DP, Rowell NR. Superficial X-ray therapy in the treatment of palmoplantar pustulosis. Br J Dermatol. 1984;111(4):499–500. doi:10.1111/j.1365-2133.1984.tb06615.x
   PubMed Web of Science ®Google Scholar
• Takahara M, Hirata Y, Nagato T, et al. Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: a retrospective subjective and objective quantitative analysis of 138 patients. J Dermatol. 2018;45(7):812–823. doi:10.1111/1346-8138.14348
   PubMed Web of Science ®Google Scholar
• Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol. 2017;44(6):695–698. doi:10.1111/1346-8138.13751
   PubMed Web of Science ®Google Scholar
• V’Lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, Kamberova SJ. Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. Dermatol Ther. 2009;22(1):85–89. doi:10.1111/j.1529-8019.2008.01219.x
   PubMedGoogle Scholar
• Ward JM, Corbett MF, Hanna MJ. A double-blind trial of clomocycline in the treatment of persistent palmoplantar pustulosis. Br J Dermatol. 1976;95(3):317–322. doi:10.1111/j.1365-2133.1976.tb07020.x
   PubMed Web of Science ®Google Scholar
• Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CEM. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145(4):546–553. doi:10.1046/j.1365-2133.2001.04411.x
   PubMed Web of Science ®Google Scholar
• Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol. 1988;119(6):755–759. doi:10.1111/j.1365-2133.1988.tb03499.x
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Chang A, van Dooren-Greebe R, Geiger JM, Happle R. Intra-epidermal accumulation of polymorphonuclear leukocytes in persistent palmoplantar pustulosis during treatment with Acitretin. Acta Derm Venereol. 1988;68(6):499‐503.
   Web of Science ®Google Scholar
• Ettler K, Benakova N, Zimova V. Acitretin therapy of palmoplantar pustulosis combined with UV-a and 8- MOP topically. Cesko-Slovenska Dermatologie. 1999;74(4):150–152.
   Google Scholar
• Aichelburg MC, Pinkowicz A, Holzer G, Radakovic S, Sator PG, Tanew A. Short- and long-term efficacy of fumaric acid esters or Acitretin in combination with a 12-week course of PUVA in the treatment of palmoplantar pustulosis: results from a prospective randomized trial. J Eur Acad Dermatol Venereol. 2021;35(3):e198‐e200. doi:10.1111/jdv.16909
   PubMed Web of Science ®Google Scholar
• Reich K, Graff O, Mehta N. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized Phase II study. Br J Dermatol. 2016;174(6):1277–1281. doi:10.1111/bjd.14401
   PubMed Web of Science ®Google Scholar
• Lee JS, Park HS, Yoon HS, Cho S. Efficacy and Safety of Oral Alitretinoin in Hand Eczema and Palmoplantar Pustulosis in Korean Patients. Ann Dermatol. 2019;31(2):139–145. doi:10.5021/ad.2019.31.2.139
   PubMed Web of Science ®Google Scholar
• Erkko P, Granlund H, Remitz A, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol. 1998;139(6):997–1004. doi:10.1046/j.1365-2133.1998.02555.x
   PubMed Web of Science ®Google Scholar
• Reitamo S, Erkko P, Remitz A, Lauerma AI, Montonen O, Harjula K. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol. 1993;129(10):1273–1279. doi:10.1001/archderm.1993.01680310043006
   PubMedGoogle Scholar
• Jin XH, Chen X, Mou Y, Xia JX. Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α. Dermatol Ther (Heidelb). 2019;9(3):547–552. doi:10.1007/s13555-019-0308-z
   PubMed Web of Science ®Google Scholar
• Remitz A, Lauerma AI, Erkko P, Reitamo S. Delayed-type hypersensitivity in palmoplantar pustulosis: effect of cyclosporin A treatment on skin testing with recall antigens. Acta Derm Venereol. 1996;76(4):310–313. doi:10.2340/0001555576310313
   PubMed Web of Science ®Google Scholar
• English JS, Fenton DA, Wilkinson JD. Failure of colchicine for palmo-plantar pustulosis. Clin Exp Dermatol. 1983;8(2):207–208. doi:10.1111/j.1365-2230.1983.tb01770.x
   PubMed Web of Science ®Google Scholar
• Mann RJ. Failure of colchicine for palmo-plantar pustulosis. Br J Dermatol. 1982;106(3):373. doi:10.1111/j.1365-2133.1982.tb01740.x
   PubMed Web of Science ®Google Scholar
• Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol. 2001;40(8):541–542. doi:10.1046/j.1365-4362.2001.01094-3.x
   PubMed Web of Science ®Google Scholar
• Poortinga S, Balakirski G, Kromer C, et al. The challenge of palmoplantar pustulosis therapy: are Interleukin-23 inhibitors an option? J Eur Acad Dermatol Venereol. 2021;35(12):e907–e911. doi:10.1111/jdv.17560
   PubMed Web of Science ®Google Scholar
• Okubo Y, Morishima H, Zheng R, Terui T. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized Phase 3 study. J Dermatol. 2021;48(12):1838–1853. doi:10.1111/1346-8138.16132
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Okubo Y, Murakami M, Hirose K, Kubo H. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: a Randomized Clinical Trial. JAMA Dermatol. 2018;154(3):309–316. doi:10.1001/jamadermatol.2017.5937
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Okubo Y, et al. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: a Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2019;155(10):1153–1161. doi:10.1001/jamadermatol.2019.1394
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344–1352. doi:10.1016/j.jaad.2019.01.066
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study. J Am Acad Dermatol. 2021;84(2):552–554. doi:10.1016/j.jaad.2020.06.038
   PubMed Web of Science ®Google Scholar
• Reolid A, Sahuquillo-Torralba A, Sanz-García A, et al. CNVs Associated with Different Clinical Phenotypes of Psoriasis and Anti-TNF-Induced Palmoplantar Pustulosis. J Pers Med. 2022;12(9):1452. doi:10.3390/jpm12091452
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28(10):1298‐1305. doi:10.1111/jdv.12272
   Web of Science ®Google Scholar
• Buder V, Herberger K, Jacobi A, Augustin M, Radtke MA. Ustekinumab in the treatment of palmoplantar pustular psoriasis – a case series of nine patients. J German Soc Dermatol. 2016;14(11):1109–1115. doi:10.1111/ddg.12825_g
   PubMed Web of Science ®Google Scholar
• Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol. 2013;168(4):820–824. doi:10.1111/bjd.12150
   PubMed Web of Science ®Google Scholar
• Bertelsen T, Kragballe K, Johansen C, Iversen L. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol. 2014;53(10):e464–466. doi:10.1111/ijd.12511
   PubMed Web of Science ®Google Scholar
• Hegazy S, Konstantinou MP, Bulai Livideanu C, Tauber M, Uthurriague C, Paul C. Efficacy of ustekinumab in palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2018;32(5):e204–e206. doi:10.1111/jdv.14718
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7(10):940‐946.
   PubMedGoogle Scholar
• Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330–2338. doi:10.1111/jdv.16265
   PubMed Web of Science ®Google Scholar
• Kromer C, Wilsmann-Theis D, Gerdes S, et al. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges. 2019;17(5):503–516.
   Web of Science ®Google Scholar
• Reolid A, Armesto S, Sahuquillo-Torralba A, et al. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. J Am Acad Dermatol. 2022;87(3):705–709. doi:10.1016/j.jaad.2022.05.047
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021;11(2):571–585. doi:10.1007/s13555-021-00504-0
   PubMed Web of Science ®Google Scholar
• Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg. 2007;11(6):202–205. doi:10.2310/7750.2007.00036
   PubMed Web of Science ®Google Scholar
• Wolk K, Wilsmann-Theis D, Witte K, et al. Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment. Int J Mol Sci. 2023;24(2):1276. doi:10.3390/ijms24021276
   PubMed Web of Science ®Google Scholar
• Wilsmann-Theis D, Kromer C, Gerdes S, et al. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS). J Eur Acad Dermatol Venereol. 2021;35(10):2045–2050. doi:10.1111/jdv.17441
   PubMed Web of Science ®Google Scholar
• Kato N, Takama H, Ando Y, et al. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study. Int J Dermatol. 2021;60(5):570–578. doi:10.1111/ijd.15382
   PubMed Web of Science ®Google Scholar
• Ständer S, Syring F, Ludwig RJ, Thaçi D. Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: a Case Series. Front Med. 2020;7. doi:10.3389/fmed.2020.543944
   Web of Science ®Google Scholar
• Soufila KT, Thakur V, Narang T, Dogra S, Handa S. Apremilast in treatment of palmoplantar pustulosis – a case series. Int J Dermatol. 2021;60(6):e247–e248. doi:10.1111/ijd.15398
   PubMed Web of Science ®Google Scholar
• Cro S, Cornelius VR, Pink AE, et al. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). Br J Dermatol. 2021;186(2):245–256. doi:10.1111/bjd.20653
   PubMed Web of Science ®Google Scholar
• Kingo K, Mössner R, Kõks S, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156(4):646–652. doi:10.1111/j.1365-2133.2006.07731.x
   PubMed Web of Science ®Google Scholar
• Hashigucci K, Yokoyama M, Niizeki H, et al. Polymorphism in the tumor necrosis factor B gene is associated with Palmoplantar pustulosis. Tissue Antigens. 1999;54(3):288–290. doi:10.1034/j.1399-0039.1999.540312.x
   PubMedGoogle Scholar
• Wang TS, Chiu HY, Hong JB, Chan CC, Lin SJ, Tsai TF. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308(1):55–63. doi:10.1007/s00403-015-1611-x
   PubMed Web of Science ®Google Scholar
• Eriksson MO, Hagforsen E, Lundin IP, Michaëlsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138(3):390–398. doi:10.1046/j.1365-2133.1998.02113.x
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Shimokawa Y, Kawauchi K, et al. Dysbiosis of Oral Microbiota Associated with Palmoplantar Pustulosis. Dermatology. 2021;237(3):347–356. doi:10.1159/000511622
   PubMed Web of Science ®Google Scholar
• Michaëlsson G, Kristjánsson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol. 2007;156(4):659–666. doi:10.1111/j.1365-2133.2006.07725.x
   PubMed Web of Science ®Google Scholar
• Sáez-Rodríguez M, Noda-Cabrera A, García-Bustínduy M, et al. Palmoplantar pustulosis associated with gastric helicobacter pylori infection [6]. Clin Exp Dermatol. 2002;27(8):720. doi:10.1046/j.1365-2230.2002.01102_6.x
   PubMed Web of Science ®Google Scholar
• Huang CM, Tsai TF. Clinical characteristics, genetics, comorbidities and treatment of palmoplantar pustulosis: a retrospective analysis of 66 cases in a single center in Taiwan. J Dermatol. 2020;47(9):1046–1049.
   PubMed Web of Science ®Google Scholar
• Gimenéz-García R, Sánchez-Ramón S, Cuellar-Olmedo LA. Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol. 2003;17(3):276–279. doi:10.1046/j.1468-3083.2003.00510.x
   PubMed Web of Science ®Google Scholar
• Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6(5):518–523. doi:10.1016/j.crohns.2011.10.007
   PubMed Web of Science ®Google Scholar
• Noe MH, Wan MT, Mostaghimi A, et al. Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States. JAMA Dermatol. 2022;158(1):68–72. doi:10.1001/jamadermatol.2021.4635
   PubMed Web of Science ®Google Scholar
• Olazagasti JM, Ma JE, Wetter DA. Clinical Features, Etiologic Factors, Associated Disorders, and Treatment of Palmoplantar Pustulosis: the Mayo Clinic Experience, 1996-2013. Mayo Clinic Proce. 2017;92(9):1351–1358. doi:10.1016/j.mayocp.2017.05.029
   PubMed Web of Science ®Google Scholar
• Putra-Szczepaniak M, Reich A, Jankowska-Konsur A, Czarnecka A, Bagłaj-Oleszczuk M, Hryncewicz-Gwóźdź A. Pack-year cigarette smoking affects the course of palmoplantar pustulosis. Adv Clin Exp Med. 2021;30(2):189–195. doi:10.17219/acem/131750
   PubMed Web of Science ®Google Scholar
• Heidemeyer K, Cazzaniga S, Dondi L, et al. Variables associated with joint involvement and development of a prediction rule for arthritis in patients with psoriasis. An analysis of the Italian PsoReal database. J Am Acad Dermatol. 2023;89(1):53–61. doi:10.1016/j.jaad.2023.02.059
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kamekura R, Kato J, et al. Cigarette Smoke Underlies the Pathogenesis of Palmoplantar Pustulosis via an IL-17A-Induced Production of IL-36γ in Tonsillar Epithelial Cells. J Invest Dermatol. 2021;141(6):1533–1541 e1534. doi:10.1016/j.jid.2020.09.028
   PubMed Web of Science ®Google Scholar
• Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006;54(4):737–738. doi:10.1016/j.jaad.2005.07.024
   PubMed Web of Science ®Google Scholar
• Reddy V, Bhutani T. Palmoplantar Pustulosis in Electronic Cigarette Users: a Potential for Concern. Dermatology. 2019;235(6):525–526. doi:10.1159/000503385
   PubMed Web of Science ®Google Scholar
• Hagforsen E, Awder M, Lefvert AK, Nordlind K, Michaëlsson G. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking? Acta Derm Venereol. 2002;82(5):341–346. doi:10.1080/000155502320624069
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kamekura R, Kamiya S, et al. Effect of cigarette smoke on interleukin-17A- and interleukin-17F-driven skin inflammation: an in vitro study. J Dermatol Sci. 2023;110(3):99–102. doi:10.1016/j.jdermsci.2023.05.002
   PubMed Web of Science ®Google Scholar
• Nakamura K, Imakado S, Takizawa M, et al. Exacerbation of pustulosis palmaris et plantaris after topical application of metals accompanied by elevated levels of leukotriene B4 in pustules. J Am Acad Dermatol. 2000;42(6):1021–1025. doi:10.1067/mjd.2000.104305
   PubMed Web of Science ®Google Scholar
• Lu JD, Lytvyn Y, Mufti A, et al. Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review. Int J Dermatol. 2023;62(1):12–21. doi:10.1111/ijd.16064
   PubMed Web of Science ®Google Scholar
• Ruwaard J, Wolbink G. Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy. J Rheumatol. 2019;46(1):117–118. doi:10.3899/jrheum.180566
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int. 2018;38(7):1297–1299. doi:10.1007/s00296-018-4034-0
   PubMed Web of Science ®Google Scholar
• Koumaki D, Koumaki V, Lagoudaki E, Bertsias G. Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis. Eur J Case Rep Intern Med. 2020;7(1):001383. doi:10.12890/2019_001383
   PubMedGoogle Scholar
• Onishi Y, Arakawa Y, Tamagawa-Mineoka R, Ohshita A, Masuda K, Katoh N. Occurrence of palmoplantar pustulosis during atezolizumab therapy for non-small cell lung cancer. J Dermatol. 2021;48(11):e570–e571. doi:10.1111/1346-8138.16144
   PubMed Web of Science ®Google Scholar
• Penalba-Torres M, Rivera-Díaz R. Palmoplantar pustulosis under secukinumab in two patients without psoriasis. J Dtsch Dermatol Ges. 2022;20(1):106–109.
   Web of Science ®Google Scholar
• Shibata T, Muto J, Hirano Y, et al. Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis. JAAD Case Rep. 2019;5(6):518–521. doi:10.1016/j.jdcr.2019.03.024
   PubMedGoogle Scholar
• Venables ZC, Swart SS, Soon CS. Palmoplantar pustulosis secondary to rituximab: a case report and literature review. Clin Exp Dermatol. 2015;40(4):451–452. doi:10.1111/ced.12527
   PubMed Web of Science ®Google Scholar
• Villalobos-Sánchez L, Larena-Grijalba C, Alía-Jiménez A, Sifuentes-Giraldo WA. Certolizumab pegol-induced palmoplantar pustulosis: a case report and review of the literature. Reumatol Clin. 2019;15(6):e163–e165. doi:10.1016/j.reuma.2017.12.004
   PubMed Web of Science ®Google Scholar
• Sarıkaya Solak S, Kara Polat A, Kilic S, et al. Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross-sectional, multicentre study of 263 patients. Clin Exp Dermatol. 2022;47(1):63–71. doi:10.1111/ced.14829
   PubMed Web of Science ®Google Scholar
• Murray D, Corbett MF, Warin AP. A controlled trial of photochemotherapy for persistent palmoplantar pustulosis. Br J Dermatol. 1980;102(6):659–663. doi:10.1111/j.1365-2133.1980.tb06565.x
   PubMed Web of Science ®Google Scholar
• Terui T, Okubo Y, Kobayashi S. 33142 Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2022;87(3):AB50‐. doi:10.1016/j.jaad.2022.06.233
   Web of Science ®Google Scholar
• Haynes D, Topham C, Hagstrom E, Greiling T. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: a case report. Australas J Dermatol. 2020;61(1):e108–e110. doi:10.1111/ajd.13117
   PubMed Web of Science ®Google Scholar
• Imafuku S, Maeyama A. Remission of anti-tumor necrosis factor-α antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis. J Dermatol. 2021;48(5):e240–e241. doi:10.1111/1346-8138.15860
   PubMed Web of Science ®Google Scholar
• Koga T, Sato T, Umeda M, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation. Clin Immunol. 2016;173:147–148. doi:10.1016/j.clim.2016.10.003
   PubMed Web of Science ®Google Scholar
• Mössner R, Hoff P, Mohr J, Wilsmann-Theis D. Successful therapy of palmoplantar pustulosis with tofacitinib-Report on three cases. Dermatol Ther. 2020;33(4):e13753. doi:10.1111/dth.13753
   PubMed Web of Science ®Google Scholar
• Gleeson D, Barker J, Capon F, et al. Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic. Br J Dermatol. 2022. doi:10.1111/bjd.20781
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Hunger RE. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and Adalimumab. Dermatology. 2009;218(1):79–83. doi:10.1159/000167802
   PubMed Web of Science ®Google Scholar
• Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70–80. doi:10.1177/2475530318810851
   PubMedGoogle Scholar
• Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845–847. doi:10.1111/j.1600-0625.2011.01325.x
   PubMed Web of Science ®Google Scholar
• Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis; Identifier, NCT04451720. Available from: https://www.clinicaltrials.gov/study/NCT04451720. Accessed September 19, 2023.
   Google Scholar
• Cro S, Cornelius V, Capon F, et al. Efficacy and Mechanism Evaluation. The Interleukin 1 Receptor Antagonist Anakinra to Reduce Disease Severity of Palmoplantar Pustulosis in Adults: APRICOT RCT and PLUM Mechanistic Study. Southampton (UK): NIHR Journals Library.
   Google Scholar
• Fukaura R, Akiyama M. Targeting IL-36 in Inflammatory Skin Diseases. BioDrugs. 2023;37(3):279–293. doi:10.1007/s40259-023-00587-5
   PubMed Web of Science ®Google Scholar
• Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 2018;28(4):538–539. doi:10.1684/ejd.2018.3325
   PubMed Web of Science ®Google Scholar
• Terui H, Moroi R, Masamune A, Aiba S, Yamasaki K. Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis. Case Rep Dermatol. 2023;15(1):22–25. doi:10.1159/000529080
   PubMed Web of Science ®Google Scholar
• Zheng YX, Zheng M, Cai SQ. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: a case report. Dermatol Ther. 2022;35(11):e15781. doi:10.1111/dth.15781
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Maari C, Tsianakas A, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021;11(6):2179–2193. doi:10.1007/s13555-021-00632-7
   PubMed Web of Science ®Google Scholar
• Deucravacitinib for the Treatment of Palmoplantar Pustulosis; IdentifierNCT05710185. Available from: https://wwwclinicaltrialsgov/study/NCT05710185. Accessed September 19, 2023.
   Google Scholar